The 2019 € 100.000 Award will be dedicated
to the promotion and recognition of excellence
in orphan disease treatment research
Milan, September 2018
The International Prize for Scientific Research Arrigo Recordati has announced the Call for Nominations for the Ninth Edition of the Award. The International Prize for Scientific Research was established in 2000 in memory of the Italian pharmaceutical entrepreneur Arrigo Recordati to carry on his legacy and to inspire researchers to make important discoveries benefiting people worldwide in the field of cardiovascular disease.
Arrigo Recordati, who passed away prematurely in 1999, strongly believed in the power of research to drive the development of the pharmaceutical industry and provide products beneficial to public health and individual wellbeing.
In the last ten years, Recordati made the Rare Diseases field a health priority and increased its commitment worldwide through its dedicated subsidiaries Orphan Europe and Recordati Rare Diseases to research, develop and market a number of treatments for orphan diseases. «To reflect our commitment, we decided that the 2019 Edition of the International Prize for Scientific Research Arrigo Recordati be dedicated to the promotion and recognition of excellence in orphan disease treatment research. The winner project will receive a research grant of € 100,000» declared the Chairman Alberto Recordati.
International projects within the area of rare/orphan disease treatment in all therapeutic areas (except for oncology, hematology and immunology) are eligible to apply as long the disease concerned has a prevalence of not more than 1 in 2000.
The 2019 Award is open to researchers of all nationalities who are not in any way directly affiliated with pharmaceutical or medical device companies.
Applications will be reviewed by an independent panel of internationally recognized experts who have provided leadership throughout their long careers in the field of Rare Diseases.
2019 Review Committee
The Review Committee for the Ninth Edition of the Award is chaired by Professor Robert J. Desnick, Ph.D., M.D., Dean for Genetic and Genomic Medicine, Professor and Chair Emeritus Department of Genetic & Genomic Sciences, Mount Sinai School of Medicine, New York, USA. The others members of the Jury are: Professor Francesco Emma M.D., Director of the Division of Pediatric Nephrology, Chief of the Department of Pediatric Subspecialties, IRCCS Children’s Hospital Bambino Gesù, Rome, Italy and Professor Norio Sakai, M.D., Ph.D., Child Healthcare and Genetic Science Laboratory, Division of Health Science, Osaka University Graduate School of Medicine, Osaka, Japan.
Nominations procedure will follow a two-step selection approach: the deadline for the preselection will be on 15th December 2018 and Full Applications must be submitted by the 30th April 2019.
The eligibility and exclusion criteria of the 2019 Award are described at:
All members of the Review Committee will assess and select the winning project according to the pre-specified Award criteria, quality of the research as well as the therapeutic impact of the results.
The winner project will be announced during an Award Ceremony at the Society for the Study of Inborn Errors of Metabolism Congress – (2019 SSIEM, Rotterdam, 2nd-6th September 2019).
The 2019 Award will be given in recognition of ongoing research projects, for which preliminary results, such as proof-of-concept and proof-of-principle, have already been obtained.
Although Recordati recognizes the value of fundamental research aimed at unraveling the disease pathophysiology/etiology, projects on orphan diseases which do not make use (or assess the potential) of an experimental treatment for a rare disease are not eligible for the Award.
If the experimental treatment is based on a pre-existing treatment, the project is only eligible if the treatment considered is being repurposed in another indication or if its formulation/administration changed in a major way, in order to improve treatment quality, compliance, efficacy, safety or any other additional patient’s benefits.
Projects concerning both medicinal products and medical devices are eligible for the Award as long as the disease treated is rare.
Recordati, a modern and dynamic international group
Recordati is an international pharmaceutical group dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Recordati is listed on the Italian Stock Exchange since 1984, is headquarted in Milan and the Group has a staff of more than 4,100. Recordati has grown constantly since 1926 thanks to the quality of its products and to the implementation of a decisive internationalization policy through a focused strategy of acquisitions and license agreements.
Recordati produces and promotes innovative medicines worldwide including both products for primary care therapies and treatments for rare diseases. In addition to the marketing of specialties generated by its original research, the Recordati group is the European partner of leading international pharmaceutical companies.
With subsidiaries in the main European countries, the U.S.A., Canada, some Latin American countries, in Japan and the Asia-Pacific regions, Russia and the Commonwealth of Independent States, Turkey and Tunisia, Recordati continues to strengthen its geographical presence.
Recordati constantly enhances its therapeutic offering through the development of its product pipeline with a focus on rare diseases, mainly treatments for metabolic deficiencies of a genetic nature. The Group operates worldwide in a highly specialized market with a significant growth potential through its dedicated subsidiaries Orphan Europe and Recordati Rare Diseases in the U.S.A.
For further information: